Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 145,445 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Rett Syndrome
Interventions: computer gaming; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 4 Years to 65 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes, NOS
Interventions: Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostate Cancer
Interventions: bevacizumab, satraplatin; Biological · Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Mild Cognitive Impairment, Dementia
Interventions: Resources and Activities for Life Long Independence (RALLI), Social Walking program (SW); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 70 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Duct Cell Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: gemcitabine hydrochloride, fluorouracil, radiation therapy, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Stroke
Interventions: EMG Band, Shoulder harness; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Overweight, Obesity
Interventions: Obesity tools in the electronic health record; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 20 Years and older
Enrollment: 65,278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Immunodeficiency
Interventions: Gamunex-C, IVIG-PEG; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • North Palm Beach, Florida • South Bend, Indiana + 6 more

Conditions: Breast Cancer
Interventions: conventional surgery, neoadjuvant therapy, radiofrequency ablation; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Sacramento, California

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 17
States / cities: Tucson, Arizona • New Haven, Connecticut • Fort Lauderdale, Florida + 14 more

Conditions: Inappropriate Sinus Tachycardia, Postural Tachycardia Syndrome
Interventions: AtriCure Commercially Available Devices; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 12
States / cities: Loma Linda, California • Palo Alto, California • Redwood City, California + 9 more

Conditions: Friedreich Ataxia
Interventions: Methylprednisolone; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Microbial Colonization, Burns
Interventions: Not listed
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 400 participants
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 39
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more

Conditions: Cognitive Impairment, Elderly
Interventions: 2g Centella asiatica water extract product, 4g Centella asiatica water extract product; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Paper Drug Diary, OhMD APP; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Empagliflozin 10 MG, Placebo; Drug
Lead sponsor: Gustavo A Heresi, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee

Conditions: Stage IV (Metastatic) Breast Cancer
Interventions: ABI-007, vinorelbine, Trastuzumab, G-CSF; Drug · Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Duarte, California • Seattle, Washington

Conditions: Major Depressive Disorder, Bipolar I and Bipolar II
Interventions: citalopram; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Cerebral Palsy
Interventions: Differential and adjustable stiffness AFO (DAS-AFO); Device
Lead sponsor: Northern Arizona University; Other
Eligibility: 8 Years to 35 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Flagstaff, Arizona

Conditions: End Stage Renal Disease on Dialysis
Interventions: Empagliflozin 25 mg vs Placebo, Empagliflozin 10 MG; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Childhood Obesity
Interventions: multi-component/setting parent-targeted intervention; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 2 Years to 4 Years
Enrollment: 534 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions: ORX750; Drug
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 19
States / cities: Auburn, Alabama • Santa Ana, California • Miami, Florida + 14 more

Search by objective public record fields.

Technology-supported Motor Rehabilitation for People With Rett Syndrome

Renal Mechanism of Action/Splay vs. TmG

Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

Exercise and Activities for Independent Living With Mild Cognitive Impairment (MCI)

Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer

MyHand: An Active Hand Orthosis for Stroke Patients

Use of Electronic Health Records for Addressing Overweight and Obesity in Primary Care

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ

Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine

Inappropriate Sinus Tachycardia Registry

Methylprednisolone Treatment of Friedreich Ataxia

Understanding the Burn Wound Microbiome: Comparing Traditional Wound Cultures to Next Generation Sequencing Technology

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

Pharmacokinetics Centella Asiatica Product (CAP) in Mild Cognitive Impairment

Correlation of HIV Levels With Clinical and Immunologic Outcome in Children Treated With Didanosine

A Study of the Use of Text Message Reminders to Take Palbociclib

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Microbiome of Depression & Treatment Response to Citalopram

Testing an Adjustable Ankle Orthosis During Walking in Cerebral Palsy

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

NET-Works:Community Preschooler Obesity Prevention

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia